Overview

Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506

Status:
Active, not recruiting
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A
Phase:
Phase 1
Details
Lead Sponsor:
Yooyoung Pharmaceutical Co., Ltd.